GB2597307A — Use of cannabidiol in the treatment of seizures associated with encephalitis

USPTO Abstract

A cannabidiol (CBD) preparation for use in the treatment of seizures associated with encephalitis is provided. The seizures associated with encephalitis may be atonic, focal seizures with impairment, focal seizures without impairment, and focal seizures with secondary generalisation. The CBD preparation may comprise greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) other cannabinoids. The CBD preparation may comprise CBD isolated from cannabis plant material or may be synthetic CBD. The CBD preparation may be used in combination with one or more concomitant anti-epileptic drugs (AED). The one or more concomitant AEDs may be selected from the group consisting of: levetiracetam, clobazam, lacosamide, and lamotrigine. The dose of CBD may be between 5 mg/kg/day to 50 mg/kg/day. A clinical trial is disclosed wherein patients diagnosed with encephalitis had a decrease in the amount of seizures after dosing with the CBD preparation and concomitant AEDs.